company background image
CYTH logo

Cyclo Therapeutics NasdaqCM:CYTH Stock Report

Last Price

US$1.40

Market Cap

US$40.2m

7D

-2.1%

1Y

57.3%

Updated

27 Mar, 2024

Data

Company Financials +

Cyclo Therapeutics, Inc.

NasdaqCM:CYTH Stock Report

Market Cap: US$40.2m

CYTH Stock Overview

Cyclo Therapeutics, Inc., a clinical stage biotechnology company, engages in the development of cyclodextrin-based products for the treatment of neurodegenerative diseases.

CYTH fundamental analysis
Snowflake Score
Valuation0/6
Future Growth2/6
Past Performance0/6
Financial Health4/6
Dividends0/6

Cyclo Therapeutics, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Cyclo Therapeutics
Historical stock prices
Current Share PriceUS$1.40
52 Week HighUS$2.57
52 Week LowUS$0.67
Beta-0.14
1 Month Change-17.65%
3 Month Change-9.09%
1 Year Change57.29%
3 Year Change-82.95%
5 Year Change-97.88%
Change since IPO-99.30%

Recent News & Updates

Recent updates

Cyclo Therapeutics GAAP EPS of -$0.41 beats by $0.12, revenue of $0.54M misses by $0.08M

Aug 16

Here's Why We're A Bit Worried About Cyclo Therapeutics' (NASDAQ:CYTH) Cash Burn Situation

Jul 12
Here's Why We're A Bit Worried About Cyclo Therapeutics' (NASDAQ:CYTH) Cash Burn Situation

We're A Little Worried About Cyclo Therapeutics' (NASDAQ:CYTH) Cash Burn Rate

Jan 20
We're A Little Worried About Cyclo Therapeutics' (NASDAQ:CYTH) Cash Burn Rate

Cyclo Therapeutics: Addressing The Fundamentals Of Alzheimer's Disease

Nov 16

Will Cyclo Therapeutics (NASDAQ:CYTH) Spend Its Cash Wisely?

Sep 28
Will Cyclo Therapeutics (NASDAQ:CYTH) Spend Its Cash Wisely?

Cyclo therapeutics to join Russell 2000 Index

Jun 14

We're Keeping An Eye On Cyclo Therapeutics' (NASDAQ:CYTH) Cash Burn Rate

Jun 12
We're Keeping An Eye On Cyclo Therapeutics' (NASDAQ:CYTH) Cash Burn Rate

Cyclo Therapeutics posts design protocol of pivotal late-stage study of Trappsol Cyclo

Apr 27

Cyclo Therapeutics' lead candidate shows durable benefit in Niemann-Pick Disease

Jan 05

How Much Is Cyclo Therapeutics, Inc. (NASDAQ:CYTH) CEO Getting Paid?

Dec 12
How Much Is Cyclo Therapeutics, Inc. (NASDAQ:CYTH) CEO Getting Paid?

Shareholder Returns

CYTHUS BiotechsUS Market
7D-2.1%0.9%0.4%
1Y57.3%10.3%28.8%

Return vs Industry: CYTH exceeded the US Biotechs industry which returned 9.6% over the past year.

Return vs Market: CYTH exceeded the US Market which returned 29.5% over the past year.

Price Volatility

Is CYTH's price volatile compared to industry and market?
CYTH volatility
CYTH Average Weekly Movement12.1%
Biotechs Industry Average Movement11.6%
Market Average Movement6.0%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.0%

Stable Share Price: CYTH's share price has been volatile over the past 3 months.

Volatility Over Time: CYTH's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
19908N. Finehttps://cyclotherapeutics.com

Cyclo Therapeutics, Inc., a clinical stage biotechnology company, engages in the development of cyclodextrin-based products for the treatment of neurodegenerative diseases. The company’s lead drug candidate is Trappsol Cyclo (hydroxypropyl beta cyclodextrin), an orphan drug, which is in Phase III clinical trials for the treatment of Niemann-Pick Type C disease; and in Phase IIb clinical trials for the treatment of Alzheimer’s disease. It also sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs.

Cyclo Therapeutics, Inc. Fundamentals Summary

How do Cyclo Therapeutics's earnings and revenue compare to its market cap?
CYTH fundamental statistics
Market capUS$40.20m
Earnings (TTM)-US$20.06m
Revenue (TTM)US$1.08m

37.3x

P/S Ratio

-2.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
CYTH income statement (TTM)
RevenueUS$1.08m
Cost of RevenueUS$98.46k
Gross ProfitUS$977.95k
Other ExpensesUS$21.04m
Earnings-US$20.06m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-0.70
Gross Margin90.85%
Net Profit Margin-1,863.36%
Debt/Equity Ratio0%

How did CYTH perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.